Last updated on July 2018

Assessing the Feasibility of BGC101 in the Treatment of PAD & CLI


Brief description of study

Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal pharmacological treatment or control of risk factors and/or had a revascularization failure, and do not have the option of further revascularization treatment.

Clinical Study Identifier: NCT02805023

Contact Investigators or Research Sites near you

Start Over

Dikla Varsano, LL.B., RN

Laniado Hospital
Netanya, Israel
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.